vTv Therapeutics (NASDAQ:VTVT – Get Free Report) and Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.
Risk & Volatility
vTv Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Earnings and Valuation
This table compares vTv Therapeutics and Enanta Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| vTv Therapeutics | $1.02 million | 118.12 | -$26.97 million | ($1.06) | -28.85 |
| Enanta Pharmaceuticals | $65.32 million | 5.33 | -$81.89 million | ($2.41) | -4.96 |
vTv Therapeutics has higher earnings, but lower revenue than Enanta Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for vTv Therapeutics and Enanta Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| vTv Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Enanta Pharmaceuticals | 1 | 0 | 5 | 0 | 2.67 |
vTv Therapeutics currently has a consensus price target of $55.83, suggesting a potential upside of 82.58%. Enanta Pharmaceuticals has a consensus price target of $21.00, suggesting a potential upside of 75.73%. Given vTv Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Enanta Pharmaceuticals.
Profitability
This table compares vTv Therapeutics and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| vTv Therapeutics | N/A | -6.27% | -5.06% |
| Enanta Pharmaceuticals | -96.89% | -61.84% | -20.70% |
Institutional and Insider Ownership
17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
vTv Therapeutics beats Enanta Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About vTv Therapeutics
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
